DelveInsight’s “Axial Spondyloarthritis Market Insights, Epidemiology and Market Forecast – 2034” report delivers an in-depth understanding of the market dynamics, competitive landscape, key growth drivers, emerging therapies, and future opportunities shaping the global axial spondyloarthritis treatment landscape.
Interested to know which axial spondyloarthritis therapies will capture the highest market share? Download the report to understand the latest axial spondyloarthritis market trends and forecasts – https://www.delveinsight.com/report-store/axial-spondyloarthritis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=akpr
Key Takeaways from the Axial Spondyloarthritis Market Report
The global axial spondyloarthritis market is anticipated to grow at a significant CAGR during the study period (2020–2034).
Axial spondyloarthritis is a multifactorial disease characterized by inflammation in sacroiliac joints and spine, bone reabsorption, and aberrant bone deposition, which may lead to ankylosis.
According to DelveInsight’s estimates, the total prevalent population of axial spondyloarthritis was approximately 4,575,000 in 2023 in the 7MM, and these cases are expected to significantly increase during the study period.
The United States accounts for the largest market size of axial spondyloarthritis in comparison to EU4 (Germany, Spain, Italy, France), the UK, and Japan.
Disease pathogenesis depends on genetic, immunological, mechanical, and bioenvironmental factors, with HLA-B27 representing the most important genetic factor.
The condition includes two distinct clinical categories: nonradiographic axial-SpA (nr-axSpA) and radiographic axial-SpA (r-axSpA), the latter traditionally known as ankylosing spondylitis (AS).
The US FDA has approved UCB’s CIMZIA, Eli Lilly’s TALTZ, Novartis’s COSENTYX, and AbbVie’s RINVOQ for treating both r-axSpA and nr-axSpA.
In December 2023, UCB announced Japan’s Ministry of Health, Labor, and Welfare approval of BIMZELX (bimekizumab) for adults with nr-axSpA and AS who do not respond well to existing treatments.
Key axial spondyloarthritis companies include Janssen Pharmaceuticals, Pfizer, UCB Biopharma, Amgen, AbbVie, Novartis, Eli Lilly and Company, and Kyowa Kirin.
Gain a competitive edge in the Axial Spondyloarthritis Market by exploring our in-depth analysis – Axial Spondyloarthritis Market Report – https://www.delveinsight.com/report-store/axial-spondyloarthritis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=akpr
Axial Spondyloarthritis Market Overview
The global axial spondyloarthritis market is evolving significantly as healthcare systems increasingly focus on early and accurate diagnosis and targeted therapeutic interventions. Axial spondyloarthritis is a type of arthritis that primarily causes pain and swelling in the spine and the sacroiliac joints, which connect the bottom of the spine to the pelvis. It can also affect other joints and is a systemic disease, potentially impacting other body parts and organs.
The condition typically begins between age 20 and 40 and is more common in men, although nr-axSpA may affect men and women equally. There is currently no complete cure for axial spondyloarthritis; however, treatment focuses on relieving pain and stiffness, maintaining spinal alignment, preventing joint damage, and improving overall quality of life. The growing global prevalence of the disease, combined with continued advancements in diagnostic capabilities and the introduction of targeted biologics and small molecule therapies, continues to fuel market growth across all major geographies.
Factors Driving the Growth of the Axial Spondyloarthritis MarketIncrease in Axial Spondyloarthritis Disease Prevalence
The global prevalence of axSpA is rising, partly due to better awareness and diagnostic capabilities. Based on DelveInsight’s assessment in 2024, the 7MM had 4.7 million prevalent cases of axSpA. These are expected to rise further due to advancements in diagnostic capabilities during the forecast period (2025–2034).
Advances in Early Diagnosis of axSpA Associated with IBD
Recent efforts in identifying biomarkers offer predictive insights into the onset, activity, and progression of axSpA associated with IBD, potentially enhancing early diagnosis and personalized treatment strategies across the 7MM.
Development of IL-17 Inhibitors
The introduction of IL-17 inhibitors such as Eli Lilly’s TALTZ, Novartis’s COSENTYX, and Kyowa Kirin’s LUMICEF has revolutionized axSpA treatment. These therapies offer targeted action with improved efficacy and safety profiles, addressing unmet medical needs and expanding treatment options for both r-axSpA and nr-axSpA patient populations.
Axial Spondyloarthritis Market Segment Analysis
The axial spondyloarthritis market is segmented by region, therapies, and analytical dimensions including KOL views, SWOT analysis, reimbursement landscape, conjoint analysis, and unmet needs assessment. Among the therapies driving market revenues, biologics including TNF inhibitors and IL-17 inhibitors account for a significant share of the treatment market, reflecting the shift away from conventional therapies toward targeted treatment approaches. In 2023, the total market size for axial spondyloarthritis therapies was approximately USD 9 million, with the majority occupied by conventional treatments, indicating substantial headroom for advanced therapy uptake during the forecast period.
Axial Spondyloarthritis Market Regional Analysis
United States is Expected to Dominate the Overall Axial Spondyloarthritis Market
The United States accounts for the largest market size of axial spondyloarthritis in comparison to EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan. As per DelveInsight’s estimates, the total diagnosed population of non-radiographic axial spondyloarthritis in the US was around 569,000 cases in 2023, supported by well-established diagnostic infrastructure, strong reimbursement frameworks, and a robust pipeline of approved and emerging therapies.
Among EU4 and UK countries, Germany had the highest number of prevalent axial spondyloarthritis cases in 2023, followed by Spain, with France recording the smallest market size within the region. Japan recorded a considerable number of axial spondyloarthritis cases in 2023, with approximately 21,300 prevalent cases, and continues to see evolving regulatory activity including the recent approval of BIMZELX for both nr-axSpA and AS.
Axial Spondyloarthritis Key Companies
Axial spondyloarthritis companies include:
Janssen Pharmaceuticals
Pfizer
UCB Biopharma
Amgen
AbbVie
Novartis
Eli Lilly and Company
Kyowa Kirin
Download the report to understand which factors are driving Axial Spondyloarthritis Market Trends
Latest Highlights from the Axial Spondyloarthritis Market
In December 2023, UCB announced that Japan’s Ministry of Health, Labor, and Welfare approved BIMZELX (bimekizumab) for adults with nr-axSpA and AS who do not respond well to existing treatments.
In June 2023, the European Commission granted marketing authorization for BIMZELX to treat adults with active axSpA, including both nr-axSpA and AS.
In December 2021, Pfizer announced US FDA approval of the supplemental New Drug Application for XELJANZ/XELJANZ XR (tofacitinib) for adults with active ankylosing spondylitis who had an inadequate response or intolerance to one or more TNF blockers.
The US FDA has approved RINVOQ (upadacitinib) from AbbVie for treating both r-axSpA and nr-axSpA, broadening the available targeted therapy options.
Advances in biomarker research are enabling earlier and more accurate diagnosis of axSpA, particularly in cases associated with inflammatory bowel disease.
Strategic collaborations between pharmaceutical companies, research institutions, and healthcare organizations continue to accelerate the development and commercialization of next-generation axSpA therapies.
Discover key developments and opportunities in the Axial Spondyloarthritis Market — Axial Spondyloarthritis Market Size
Axial Spondyloarthritis Market Outlook
The axial spondyloarthritis market is experiencing steady growth as healthcare systems increasingly prioritize early diagnosis, targeted biologic therapy, and personalized treatment strategies. The expanding use of IL-17 inhibitors, JAK inhibitors, and TNF blockers, alongside a growing understanding of disease pathogenesis, is transforming the treatment landscape across all major geographies.
The market is also benefiting from expanding applications of precision medicine, growing biomarker research, and increasing regulatory support for novel axSpA therapies across the United States, European markets, and Japan. As diagnostic capabilities continue to improve and new therapies advance through the pipeline, the axial spondyloarthritis market is positioned for sustained growth, enabling earlier therapeutic intervention, improved patient outcomes, and more personalized disease management strategies across the 7MM through 2034.
Scope of the Axial Spondyloarthritis Market Report
Study Period: 2020–2034
Forecast Period: 2024–2034
Geographies Covered: United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan
Major Axial Spondyloarthritis Companies: Janssen Pharmaceuticals, Pfizer, UCB Biopharma, Amgen, AbbVie, Novartis, Eli Lilly and Company, and Kyowa Kirin
Market Segments Covered: Region, Therapies, KOL Views, SWOT Analysis, Reimbursement, Conjoint Analysis, and Unmet Needs
Epidemiology Segments Covered: Total Prevalent Cases, Total Diagnosed Prevalent Cases, Gender-specific Cases, Gene-specific Cases, Age-specific Cases, and Total Treated Cases of Axial Spondyloarthritis in the 7MM (2020–2034)
Key Focus Areas: IL-17 Inhibitors, JAK Inhibitors, TNF Blockers, Biomarker-Driven Early Diagnosis, Precision Medicine, and Emerging Pipeline Therapies
Table of Contents
Key Insights
Report Introduction
Axial Spondyloarthritis (axSpA) Market Overview at a Glance
Axial Spondyloarthritis Methodology
Executive Summary
Disease Background and Overview
Treatment of Axial Spondyloarthritis (axSpA)
Epidemiology and Patient Population
Axial Spondyloarthritis Patient Journey
Axial Spondyloarthritis Marketed Therapies
Market Analysis
KOL Views
SWOT Analysis
Axial Spondyloarthritis Unmet Needs
Market Access and Reimbursement
Appendix
DelveInsight Capabilities
Disclaimer
How DelveInsight’s Axial Spondyloarthritis Market Report Helps CXOs and Business Leaders
Evaluate the current and future market opportunity across key regions, including the United States, EU4, and Japan, through detailed market forecasts, therapy assessments, and epidemiology-driven growth trend analysis.
Benchmark leading axial spondyloarthritis therapies and diagnostic approaches through comprehensive competitive intelligence, company profiling, drug portfolio evaluation, and clinical trial tracking.
Identify potential licensing, co-development, and strategic partnership opportunities by monitoring emerging market participants, novel mechanism therapies, and recent industry collaborations, mergers, and investments.
Assess the impact of upcoming regulatory approvals, pipeline advancements, reimbursement developments, and product launches on market share, pricing strategies, adoption rates, and commercial success across the 7MM.
Support strategic decision-making with insights into key opinion leader perspectives, unmet therapeutic needs, clinical adoption trends, biomarker utilization, patient stratification approaches, and evolving market dynamics within the axial spondyloarthritis landscape.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Media ContactCompany Name: DelveInsight Business ResearchContact Person: Abhishek kumarEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/report-store/axial-spondyloarthritis-market
